Genentech

Genentech articles from Informachine.

Genentech, OSI to pay $67 mn to settle false claims on cancer drug Tarceva

08 Jun 2016

23andMe Inc, Genentech to analyse genomes of 3,000 Parkinson’s patients

09 Jan 2015

Genentech to pay up to $1.7 bn for oncology firm Seragon

03 Jul 2014

GSK sues Roche over Genentech's cancer drug patent infringement

23 Sep 2010

Roche confirms plans to acquire remaining 44 per cent in Genentech

21 Oct 2008

Genentech rejects Roche’s $43.7-billion takeover offer as too low

13 Aug 2008

Biotechnology giant Genentech Inc today rejected a $43.7-billion takeover bid from its majority shareholder, Roche Holding AG, as too low, while saying it would be open to a higher proposal.

Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.

Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!

Start your free subscription today!

Latest articles on Genentech from Informachine

$FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma$

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

19 Jun 2026

Filing acceptance based on data from the Phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

19 Jun 2026

Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone.